Impact of Exercise Timing on Blood Sugar Control in Overweight Type 1 Diabetes Patients
Elucidating the Interplay Between Circadian Rhythm and Physical Exercise on Metabolism in Patients With Type 1 Diabetes and Overweight
This study is testing whether doing high intensity workouts in the morning or afternoon helps people with type 1 diabetes better control their blood sugar levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | All |
| Sponsor | Karolinska Institutet Academic / other |
| Locations | 1 site (Stockholm) |
| Trial ID | NCT05277532 on ClinicalTrials.gov |
What this trial studies
This project investigates how the timing of high intensity interval training (HIIT) affects glucose control and muscle metabolism in overweight individuals with type 1 diabetes. The study will compare the effects of morning versus afternoon HIIT sessions on blood glucose levels, utilizing continuous glucose monitoring for precise measurements. A total of 50 participants, including 25 with type 1 diabetes and 25 healthy controls, will undergo a randomized cross-over design to assess the metabolic responses to exercise at different times of the day.
Who should consider this trial
Good fit: Ideal candidates include overweight individuals with a BMI between 25-30, either diagnosed with type 1 diabetes or healthy.
Not a fit: Patients with cardiovascular disease, significant hypertension, or other serious health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into optimizing exercise regimens for better glucose management in overweight patients with type 1 diabetes.
How similar studies have performed: While the interplay of circadian rhythms and exercise is a relatively novel area, previous studies have shown promising results with HIIT in managing diabetes, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI 25-30 * type 1 diabetes or healthy subjects Exclusion Criteria: * nicotine usage, * cardiovascular disease (CVD), * blood pressure \>160/95, * pregnancy, * treatment with other pharmaceutical drugs than insulin, stable dose of thyroid hormone, statins, and antihypertensive drugs (excluding beta blockers). Additional exclusion criteria for diabetes subjects: * diabetes duration less than 6 months, * proliferative or severe non-proliferative retinopathy, * chronic kidney disease with glomerular filtration rate (GFR) \<60 ml/min,
Where this trial is running
Stockholm
- Ersta sjukhus — Stockholm, Sweden (Recruiting)
Study contacts
- Principal investigator: Ingrid Dahlman, Professor — Karolinska Institutet
- Study coordinator: Eva Toft, Assoc Prof
- Email: eva.toft@ki.se
- Phone: +46 706722363
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.